Spevigo® (spesolimab-sbzo) – Expanded indication
March 19, 2024 - Boehringer Ingelheim announced the FDA approval of Spevigo (spesolimab-sbzo), for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.
Download PDF
